Immunotherapy has transformed cancer treatment in the past decade, with combinations of immune checkpoint inhibitors and conventional therapies showing promise across various cancers.This study reviews ongoing clinical trials of T cell receptor-T cell (TCR-T) therapies, analyzing their potential in targeting key cancer antigens for future treatment advancements.We examined data from ClinicalTrials.gov,focusing on phase 1-4 trials with reported results up to August 31, 2024.Trials were selected based on relevance to TCR-T cell therapy, safety and efficacy evaluation, and predefined inclusion/exclusion criteria.Thirty-three TCR-T clinical trials were identified, with 17 focusing on advanced cancers.Target antigens included New York esophageal squamous cell carcinoma (16 trials), melanoma-associated antigen (5 trials), and human papillomavirus 16 E (4 trials).Most studies targeted adults, with three involving pediatric patients.Sponsors included the National Cancer Institute and GlaxoSmithKline, with melanoma being the most studied cancer.One trial (NCT05066165) utilized CRISPR/Cas9 for non-viral TCR gene editing.Recent FDA approval of afamitresgene autoleucel, the first gene-modified TCR-T cell therapy targeting solid tumors, marks a significant milestone.TCR-T therapies are evolving into personalized cancer treatments, with shared antigenbased therapies leading development.The introduction of CRISPR technology is expected to enhance the efficiency and safety of gene-modified therapies, shaping the future of cancer immunotherapy.This review highlights the rapidly advancing field of TCR-T cell therapies and their potential to revolutionize cancer treatment.